CL2009000651A1 - Forma anhidra ii, forma hemi pentahidrato y forma solvato metanol de la sal del acido lactico 4-amino-5-fluoro-3-[5-(4-metil piperazin-1-il)1h-benzimidazol-2-il]quinolin-2-(1h)-ona; composición farmacéutica que las comprende; y uso para tratar enfermedades que inhiben la actividad de vegfr2 y fgfr3, tales como cáncer. - Google Patents
Forma anhidra ii, forma hemi pentahidrato y forma solvato metanol de la sal del acido lactico 4-amino-5-fluoro-3-[5-(4-metil piperazin-1-il)1h-benzimidazol-2-il]quinolin-2-(1h)-ona; composición farmacéutica que las comprende; y uso para tratar enfermedades que inhiben la actividad de vegfr2 y fgfr3, tales como cáncer.Info
- Publication number
- CL2009000651A1 CL2009000651A1 CL2009000651A CL2009000651A CL2009000651A1 CL 2009000651 A1 CL2009000651 A1 CL 2009000651A1 CL 2009000651 A CL2009000651 A CL 2009000651A CL 2009000651 A CL2009000651 A CL 2009000651A CL 2009000651 A1 CL2009000651 A1 CL 2009000651A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- benzimidazol
- quinolin
- fluoro
- amino
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 title 3
- 101100540419 Danio rerio kdrl gene Proteins 0.000 title 1
- 101150025764 FGFR3 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000004686 pentahydrates Chemical group 0.000 title 1
- -1 4-methylpiperazin-yl Chemical group 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 208000003747 lymphoid leukemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3774608P | 2008-03-19 | 2008-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009000651A1 true CL2009000651A1 (es) | 2010-07-19 |
Family
ID=40622140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009000651A CL2009000651A1 (es) | 2008-03-19 | 2009-03-18 | Forma anhidra ii, forma hemi pentahidrato y forma solvato metanol de la sal del acido lactico 4-amino-5-fluoro-3-[5-(4-metil piperazin-1-il)1h-benzimidazol-2-il]quinolin-2-(1h)-ona; composición farmacéutica que las comprende; y uso para tratar enfermedades que inhiben la actividad de vegfr2 y fgfr3, tales como cáncer. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8563556B2 (https=) |
| EP (1) | EP2257544B1 (https=) |
| JP (1) | JP2011515370A (https=) |
| KR (1) | KR20100137517A (https=) |
| CN (1) | CN101970425B (https=) |
| AR (1) | AR070924A1 (https=) |
| AU (1) | AU2009227003B2 (https=) |
| BR (1) | BRPI0909762A2 (https=) |
| CA (1) | CA2718076A1 (https=) |
| CL (1) | CL2009000651A1 (https=) |
| CO (1) | CO6321253A2 (https=) |
| EC (1) | ECSP10010555A (https=) |
| IL (1) | IL208020A0 (https=) |
| MA (1) | MA32230B1 (https=) |
| MX (1) | MX2010010152A (https=) |
| MY (1) | MY150554A (https=) |
| NZ (2) | NZ600887A (https=) |
| PE (1) | PE20091628A1 (https=) |
| PH (2) | PH12012502568A1 (https=) |
| RU (1) | RU2497820C2 (https=) |
| SG (1) | SG188919A1 (https=) |
| TW (1) | TWI426072B (https=) |
| WO (1) | WO2009115562A2 (https=) |
| ZA (1) | ZA201006263B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| ES2707625T3 (es) | 2010-04-16 | 2019-04-04 | Novartis Ag | Compuesto orgánico para su utilización en el tratamiento del cáncer de hígado |
| NZ602807A (en) | 2010-04-16 | 2014-02-28 | Novartis Ag | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor |
| UY33472A (es) * | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| WO2012125812A1 (en) | 2011-03-17 | 2012-09-20 | Novartis Ag | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects |
| BR112013029246A2 (pt) | 2011-05-19 | 2017-02-14 | Novartis Ag | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico |
| JP2014526506A (ja) | 2011-09-15 | 2014-10-06 | ノバルティス アーゲー | 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用 |
| WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
| JP2015505562A (ja) | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
| US20150202203A1 (en) | 2012-07-11 | 2015-07-23 | Novartis Ag | Method of Treating Gastrointestinal Stromal Tumors |
| WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304344B6 (cs) * | 2000-09-11 | 2014-03-19 | Novartis Vaccines & Diagnostics, Inc. | Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu |
| US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| CA2496164C (en) * | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| AU2003290699B2 (en) | 2002-11-13 | 2009-08-27 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| CN100377709C (zh) * | 2002-11-13 | 2008-04-02 | 希龙公司 | 受体酪氨酸激酶抑制剂的制药用途及相关检测方法 |
| CN102225926A (zh) * | 2003-11-07 | 2011-10-26 | 诺华疫苗和诊断公司 | 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐 |
| US7875624B2 (en) * | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
| KR101387985B1 (ko) * | 2005-01-27 | 2014-04-25 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 전이 종양의 치료 |
| MX2007014782A (es) * | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
| RU2433826C2 (ru) * | 2005-11-29 | 2011-11-20 | Новартис Аг | Композиции хинолинонов |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
-
2009
- 2009-03-17 PE PE2009000395A patent/PE20091628A1/es not_active Application Discontinuation
- 2009-03-17 AR ARP090100957A patent/AR070924A1/es unknown
- 2009-03-18 NZ NZ600887A patent/NZ600887A/xx not_active IP Right Cessation
- 2009-03-18 CN CN200980108402.0A patent/CN101970425B/zh not_active Expired - Fee Related
- 2009-03-18 MY MYPI20104156 patent/MY150554A/en unknown
- 2009-03-18 US US12/922,213 patent/US8563556B2/en not_active Expired - Fee Related
- 2009-03-18 WO PCT/EP2009/053222 patent/WO2009115562A2/en not_active Ceased
- 2009-03-18 BR BRPI0909762A patent/BRPI0909762A2/pt not_active IP Right Cessation
- 2009-03-18 NZ NZ587829A patent/NZ587829A/xx not_active IP Right Cessation
- 2009-03-18 KR KR1020107023196A patent/KR20100137517A/ko not_active Ceased
- 2009-03-18 CL CL2009000651A patent/CL2009000651A1/es unknown
- 2009-03-18 JP JP2011500221A patent/JP2011515370A/ja active Pending
- 2009-03-18 EP EP09721534.7A patent/EP2257544B1/en active Active
- 2009-03-18 SG SG2013020011A patent/SG188919A1/en unknown
- 2009-03-18 CA CA2718076A patent/CA2718076A1/en not_active Abandoned
- 2009-03-18 RU RU2010142396/04A patent/RU2497820C2/ru not_active IP Right Cessation
- 2009-03-18 MX MX2010010152A patent/MX2010010152A/es not_active Application Discontinuation
- 2009-03-18 TW TW098108804A patent/TWI426072B/zh not_active IP Right Cessation
- 2009-03-18 AU AU2009227003A patent/AU2009227003B2/en not_active Ceased
-
2010
- 2010-09-01 ZA ZA2010/06263A patent/ZA201006263B/en unknown
- 2010-09-06 IL IL208020A patent/IL208020A0/en not_active IP Right Cessation
- 2010-10-15 MA MA33250A patent/MA32230B1/fr unknown
- 2010-10-19 EC EC2010010555A patent/ECSP10010555A/es unknown
- 2010-10-19 CO CO10129430A patent/CO6321253A2/es not_active Application Discontinuation
-
2012
- 2012-12-26 PH PH12012502568A patent/PH12012502568A1/en unknown
- 2012-12-26 PH PH12012502569A patent/PH12012502569A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ587829A (en) | 2012-08-31 |
| KR20100137517A (ko) | 2010-12-30 |
| WO2009115562A2 (en) | 2009-09-24 |
| EP2257544A2 (en) | 2010-12-08 |
| WO2009115562A3 (en) | 2009-11-26 |
| AU2009227003A1 (en) | 2009-09-24 |
| AR070924A1 (es) | 2010-05-12 |
| PH12012502569A1 (en) | 2015-09-21 |
| MA32230B1 (fr) | 2011-04-01 |
| MX2010010152A (es) | 2010-10-25 |
| RU2497820C2 (ru) | 2013-11-10 |
| CN101970425A (zh) | 2011-02-09 |
| TW201000463A (en) | 2010-01-01 |
| AU2009227003B2 (en) | 2013-03-14 |
| CO6321253A2 (es) | 2011-09-20 |
| ECSP10010555A (es) | 2010-11-30 |
| HK1147492A1 (en) | 2011-08-12 |
| IL208020A0 (en) | 2010-12-30 |
| NZ600887A (en) | 2013-10-25 |
| CN101970425B (zh) | 2014-04-16 |
| CA2718076A1 (en) | 2009-09-24 |
| JP2011515370A (ja) | 2011-05-19 |
| EP2257544B1 (en) | 2014-12-03 |
| ZA201006263B (en) | 2011-05-25 |
| TWI426072B (zh) | 2014-02-11 |
| US8563556B2 (en) | 2013-10-22 |
| US20110021536A1 (en) | 2011-01-27 |
| RU2010142396A (ru) | 2012-04-27 |
| PH12012502568A1 (en) | 2014-10-27 |
| PE20091628A1 (es) | 2009-11-19 |
| MY150554A (en) | 2014-01-30 |
| BRPI0909762A2 (pt) | 2018-04-03 |
| SG188919A1 (en) | 2013-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000651A1 (es) | Forma anhidra ii, forma hemi pentahidrato y forma solvato metanol de la sal del acido lactico 4-amino-5-fluoro-3-[5-(4-metil piperazin-1-il)1h-benzimidazol-2-il]quinolin-2-(1h)-ona; composición farmacéutica que las comprende; y uso para tratar enfermedades que inhiben la actividad de vegfr2 y fgfr3, tales como cáncer. | |
| PH12019501350B1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| MX374401B (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso para tratar cancer. | |
| CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
| MX2020011558A (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm. | |
| CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| CA2919397C (en) | Aryl ethers as hif-2.alpha. inhibitors for the treatment of cancer | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| UY35633A (es) | Inhibidores de bromodominios | |
| NI201500123A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CO6351786A2 (es) | Inkibidores de la cinasa map p38 | |
| NI201100052A (es) | Derivados de picolinamida como inhibidores de cinasa. | |
| MX2011009847A (es) | Agentes antihelminticos y su uso. | |
| HN2011000193A (es) | Derivados de piridazina como inhibidores de smo | |
| CU20120101A7 (es) | Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| CL2013002870A1 (es) | Sal diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida; método de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento o profilaxis del cáncer. | |
| MX2015014234A (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| IN2012DN01983A (https=) | ||
| CU20110159A7 (es) | Pirimidinas fusionadas | |
| UA112795C2 (uk) | Біциклічні піразинонові похідні | |
| CL2012000582A1 (es) | Formas polimorfas de 5-amino-1-(4-(4-clorobenzoil)-3,5-diclorobencil)-1,2,3-triazol-4-carboxamida y de su sal de acido orotico; metodos de preparacion; y uso en el tratamiento de canceres solidos, degeneracion macular, retinopatia, leucemia mieloide cronica y sida. |